| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 77,775 | 76,662 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 114,589 | 85,448 |
| Cash and cash equivalents at beginning of period | 53,550 | - |
| Cash and cash equivalents at end of period | 168,139 | - |
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA)